Region-specific changes in 5-HT(1A) receptor-activated G-proteins in rat brain following chronic buspirone

European Journal of Pharmacology

Volumn 389, Issue 2-3, 2000, Pages 147-153

  Sim Selley, Laura J ^a   Vogt, Leslie J ^b   Xiao, Ruoyu ^b   Childers, Steven R ^b   Selley, Dana E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT(1A) receptor; 35S GTP S autoradiography; Antidepressant; Anxiolytic; G protein; GABA(B) receptor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 AMINOBUTYRIC ACID B RECEPTOR; BACLOFEN; BUSPIRONE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPTUM PELLUCIDUM;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BRAIN CHEMISTRY; BUSPIRONE; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-B; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1;

EID: 0034681324     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00875-4     Document Type: Article

References (50)

1. B receptors to the same channels in hippocampus. Science. 234:1986;1261-1265.
2. Angrini M., Leslie J.C., Shephard R.A. Effects of propranolol, buspirone, pCPA, reserpine and chlordiazepoxide on open-field behavior. Pharmacol. Biochem. Behav. 59:1998;387-397.
3. B receptor-mediated hyperpolarization in area CA1, but not area CA3, hippocampal pyramidal cells. J. Pharmacol. Exp. Ther. 281:1997;115-122.
4. Blier P., Chaput Y., De Montigny C. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 337:1988;246-254.
5. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse. 1:1987;470-480.
6. 1A receptor agonists. J. Cardiovasc. Pharmacol. 15:1990;S42-S48.
7. 1A receptors negatively coupled with adenylyl cyclase in hippocampal neurons. Naunyn-Schmiedeberg's Arch. Pharmacol. 335:1987;588-592.
8. 9-tetrahydrocannabinol produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G-proteins in rat brain. J. Neurochem. 73:1999;2447-2459.
9. Cadieux R.J. Azapirones: an alternative to benzodiazepines for anxiety. Am. Fam. Physician. 15:1996;2349-2353.
10. Clarke W.P., De Vivo M., Beck S.G., Maayani S., Goldfarb J. Serotonin decreases population spike amplitude in hippocampal cells through a pertussis toxin substrate. Brain Res. 410:1987;357-361.
11. 1A receptor antagonists. Psychopharmacology. 119:1995;47-54.
12. 1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J. Pharmacol. Exp. Ther. 238:1986;248-253.
13. Enberg G. A metabolite of buspirone increases locus coeruleus activity via alpha2-receptor blockade. J. Neural Transm. 76:1989;91-98.
14. 1A receptor. J. Biol. Chem. 264:1989;14848-14852.
15. Goldberg H.L., Finnerty R.J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry. 136:1979;1184-1187.
16. i-adenylate cyclase complex in rat hippocampus. Eur. J. Pharmacol. 154:1988;95-98.
17. Hedlund L., Wahlstrom G. Buspirone as an inhibitor of voluntary ethanol intake in male rats. Alcohol Alcohol. 31:1996;149-156.
18. Hjorth S., Carlsson A. Buspirone: effects on central monoaminergic transmissionpossible relevance to animal experimental and clinical findings. Eur. J. Pharmacol. 83:1982;299-303.
19. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
20. B-induced hyperpolarization of rat dorsal raphe neurons. Brain Res. 459:1988;27-36.
21. 1A receptors in rats treated chronically with a novel antidepressant, cericlamine. J. Pharmacol. Exp. Ther. 268:1994;1432-1443.
22. Kia H.K., Brisorgueil M.J., Hamon M., Calas A., Verge D. Ultrastructural localization of 5-hydroxytryptamine1A receptors in the rat brain. J. Neurosci. Res. 46:1996;697-708.
23. B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J. Pharmacol. Exp. Ther. 235:1985;191-199.
24. Malec T.S., Malec E.A., Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin. Exp. Res. 20:1996;853-858.
25. 1A-mediated inhibition of serotonin synthesis: Possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol. Pharmacol. 37:1990;231-237.
26. 35S]GTPγS binding in brain: modulation by endogenous adenosine. Neuropharmacology. 1999;. in press.
27. B receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res. 709:1996;215-220.
28. 1A agonists and antidepressants. J. Pharmacol. Exp. Ther. 260:1992;16-20.
29. 1A receptors. Eur. J. Pharmacol. 307:1996;107-111.
30. O'Connell M.T., Curzon G. A comparison of the effects of 8-OH-DPAT pretreatment on different behavioural responses to 8-OH-DPAT. Eur. J. Pharmacol. 312:1996;137-143.
31. B, and pirenzapine-insensitive muscarinic receptors are functionally coupled to distinct pools of the same kind of G-proteins in rat hippocampus. Brain Res. 689:1995;129-135.
32. 1A agonist buspirone on serotonin synthesis in the rat. J. Neurochem. 72:1999;2022-2031.
33. Palacios J.M., Waeber C., Hoyer D., Mengod G. Distribution of serotonin receptors. Ann. N. Y. Acad. Sci. 1990;36-52.
34. Pazos A., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain: I. Serotonin-1 receptors. Brain Res. 346:1985;205-230.
35. Pecknold J.C. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf. 16:1997;118-132.
36. Rickels K., Weisman K., Norstad N., Singer M., Stoltz D., Brown A., Danton J. Buspirone and diazepam in anxiety: a controlled study. J. Clin. Psychiatry. 43:1982;81-86.
37. Schechter L.E., Bolanos F.J., Gozlan H., Lanfumey L., Haj-Dahmane S., Laporte A.M., Fattaccini C.M., Hamon M. Alterations of central serotonergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J. Pharmacol. Exp. Ther. 255:1990;1335-1347.
38. Sijbesma H., Schipper J., Cornelissen J.C.H.M., De Kloet E.R. Species differences in the distribution of central 5-HT1 binding sites: a comparative autoradiographic study between rat and guinea pig. Brain Res. 555:1991;295-304.
39. 35S]GTPγS autoradiography in rat brain. J. Neurosci. 16:1996;8057-8066.
40. 35S]GTPγS binding in rat brain: Evidence for partial agonist activity at μ-opioid receptors. J. Neurochem. 70:1998;1567-1576.
41. 35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. U.S.A. 92:1995;7242-7246.
42. 35S]GTPγS binding. Challiss R.A. Methods in Molecular Biology: Receptor Signal Transduction Protocols. 1997;117-132 Humana, Totowa, NJ.
43. 35S]GTPγS autoradiography in rat brain. J. Neurosci. 16:1996b;2684-2692.
44. 1A receptor-activated G-proteins in rat brain. Brain Res. Bull. 44:1997;39-45.
45. Smith L.M., Peroutka S.J. Differential effects of 5-hydroxytryptamine1A selective drugs on the 5-HT behavioral syndrome. Pharmacol. Biochem. Behav. 24:1986;1513-1519.
46. 1B agonists. Synapse. 1:1987;3-9.
47. Sussman N. Anxiolytic antidepressant augmentation. J. Clin. Psychiatry. 59:1998;49-50.
48. Thase M.E., Howland R.H., Friedman E.S. Treating antidepressant nonresponders with augmentation strategies: an overview. J. Clin. Psychiatry. 59:1998;5-12.
49. 1A-sensitive adenylyl cyclase of rodent hippocampal neurons: effects of antidepressant treatments and chronic stimulation with agonists. J. Pharmacol. Exp. Ther. 257:1991;433-438.
50. 1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci. 6:1986;3474-3482.